Insmed (INSM) Other Non-Current Liabilities (2011 - 2026)
Insmed (INSM) posted quarterly Other Non-Current Liabilities of $5.7 million for Q1 2026, down 96.96% year-over-year from $187.2 million in Q1 2025, and up 0.67% quarter-over-quarter from $5.6 million in Q4 2025.
Insmed (INSM) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 96.96% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 96.96% YoY), while the FY2025 annual figure was $5.6 million, down 96.66% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $5.7 million, up from $5.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $187.2 million in Q1 2025, with the low at $5.6 million in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $62.1 million (2022), against an average of $72.1 million.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities soared 2075.64% in 2024, then plunged 96.96% in 2026.
- Insmed's Other Non-Current Liabilities stood at $58.1 million in 2022, then surged by 45.61% to $84.6 million in 2023, then surged by 99.65% to $168.9 million in 2024, then tumbled by 96.66% to $5.6 million in 2025, then advanced by 0.67% to $5.7 million in 2026.
- Business Quant data shows INSM's Other Non-Current Liabilities at $5.7 million in Q1 2026, $5.6 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.55 Mn |
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 180.50 Mn |
| Mar 31, 2025 | 187.20 Mn |
| Dec 31, 2024 | 168.90 Mn |
| Jun 30, 2024 | 169.70 Mn |
| Mar 31, 2024 | 73.40 Mn |
| Dec 31, 2023 | 84.60 Mn |
| Sep 30, 2023 | 69.90 Mn |
| Jun 30, 2023 | 7.80 Mn |
| Mar 31, 2023 | 6.20 Mn |
| Dec 31, 2022 | 58.10 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 55.60 Mn |
| Mar 31, 2022 | 66.12 Mn |
| Dec 31, 2021 | 75.67 Mn |
| Sep 30, 2021 | 23.88 Mn |
| Jun 30, 2021 | 12.81 Mn |